iPSC-7---converted-with-Clipchamp-(1)-(1) (1)

Our mission is the delivery of ethically-approved, quality-controlled safe iPSC lines for medical research, affordable regenerative medicine and treatment.

Cellagility Biomed will own iPSC regenerative medicine products, services and technologies, the building block for a variety of human cells and tissue models for science, drug discovery, toxicology and therapy.

LATEST PUBLICATION

400-400._2jpg

Chemically defined and growth-factor-free culture system for the expansion and derivation of human pluripotent stem cells

Nature Biomedical Engineering volume 2, pages173–182(2018)

doi:10.1038/s41551-018-0200-7

READ MORE

LATEST NEWS

400-400._1jpg

March 5, 2018

Press release- Culturing cheaper stem cells, a new combination of chemical compounds could lead the way to more cost-effective stem cell cultures – Kouichi Hasegawa, PhD, Scientific Advisor, Cell agility Biomed Private Limited

READ MORE

February 28, 2018

Cellagility team participates in the SPIRITS International symposium- 2018 on “Multidisciplinary Approaches for Cell Control” at Kyoto University

READ MORE